Dolby Laboratories, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD from Q3 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Dolby Laboratories, Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and growth rate from Q3 2017 to Q3 2024.
  • Dolby Laboratories, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending September 27, 2024 was $578M, a 29.4% decline year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $578M -$240M -29.4% Sep 27, 2024 10-K 2024-11-19
Q2 2024 $779M -$20.5M -2.57% Jun 28, 2024 10-Q 2024-08-07
Q1 2024 $824M +$131M +18.9% Mar 29, 2024 10-Q 2024-05-02
Q4 2023 $709M +$77.2M +12.2% Dec 29, 2023 10-Q 2024-02-02
Q3 2023 $818M +$190M +30.2% Sep 29, 2023 10-K 2024-11-19
Q2 2023 $799M -$68.1M -7.85% Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $693M -$215M -23.7% Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $631M -$433M -40.7% Dec 30, 2022 10-Q 2024-02-02
Q3 2022 $628M -$605M -49% Sep 30, 2022 10-K 2024-11-19
Q2 2022 $867M -$360M -29.3% Jul 1, 2022 10-Q 2023-08-03
Q1 2022 $909M -$205M -18.4% Apr 1, 2022 10-Q 2023-05-05
Q4 2021 $1.06B -$55M -4.91% Dec 31, 2021 10-Q 2023-02-02
Q3 2021 $1.23B +$153M +14.2% Sep 24, 2021 10-K 2024-11-19
Q2 2021 $1.23B +$364M +42.1% Jun 25, 2021 10-Q 2022-08-09
Q1 2021 $1.11B +$379M +51.6% Mar 26, 2021 10-Q 2022-05-05
Q4 2020 $1.12B +$366M +48.6% Dec 25, 2020 10-Q 2022-02-04
Q3 2020 $1.08B +$274M +34.1% Sep 25, 2020 10-K 2023-11-17
Q2 2020 $863M +$139M +19.2% Jun 26, 2020 10-Q 2021-07-29
Q1 2020 $734M -$422K -0.06% Mar 27, 2020 10-Q 2021-05-04
Q4 2019 $753M -$46.6M -5.83% Dec 27, 2019 10-Q 2021-01-29
Q3 2019 $806M -$120M -12.9% Sep 27, 2019 10-K 2022-11-18
Q2 2019 $724M -$113M -13.5% Jun 28, 2019 10-Q 2020-08-03
Q1 2019 $735M +$21.3M +2.98% Mar 29, 2019 10-Q 2020-05-04
Q4 2018 $800M +$196M +32.4% Dec 28, 2018 10-Q 2020-01-29
Q3 2018 $925M +$291M +45.9% Sep 28, 2018 10-K 2021-11-17
Q2 2018 $837M Jun 29, 2018 10-Q 2019-08-02
Q1 2018 $714M Mar 30, 2018 10-Q 2019-05-08
Q4 2017 $604M Dec 29, 2017 10-Q 2019-02-01
Q3 2017 $634M Sep 29, 2017 10-K 2020-11-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.